MY ACCOUNT | NEWSLETTER |

The US Drug Agency has to remember the risks of self-medicating with ivermectin against COVID-19

The FDA warns that this product is used primarily for veterinary treatments due to the increase in hospitalizations from taking it.


“You are not a horse. You are not a cow ”. In these terms, the United States Food and Drug Administration (FDA) has had to appeal to the public in light of the increase in reports received from patients who have required medical assistance and have been hospitalized after self-medicating with ivermectin, a product used mainly as veterinary medicine. The reason for these cases has been the mistaken belief that ivermectin is used to treat humans against COVID-19.

The FDA admits that given the number of deaths the coronavirus has caused, it is not surprising that some consumers are seeking unconventional, unapproved or agency-sanctioned treatments, and see this as understandable. However, also remember that in the United States, the use of any treatment for COVID-19 that is not approved or authorized by the FDA, unless it is part of a clinical trial, can be very dangerous and cause serious harm.

Taking large doses of this medicine is dangerous

Thus, the FDA has had to remember that it has not approved the use of ivermectin to treat or prevent COVID-19 in humans and that taking large doses of this drug is dangerous and can cause serious harm.

The FDA clarifies that some formulations of ivermectin are used in animals to prevent heartworm disease and certain internal and external parasites, and insists that it is important to note that these products are different from those used for people and that They are safe when used as prescribed for animals only.

Likewise, he has had to explain that veterinary drugs are usually highly concentrated because they are used for large animals such as horses and cows and that such high doses can be very toxic to humans.

Use of ivermectin in humans

In the United States, the FDA has approved the use of ivermectin tablets in humans to treat people with strongyloidiasis and intestinal onchocerciasis, two conditions caused by parasitic worms. Additionally, some topical forms of ivermectin are approved to treat external parasites such as lice and for skin conditions such as rosacea. However, ivermectin is not an antiviral, underlines the US agency.

However, the belief that taking large doses of ivermectin is effective against COVID-19 has been reported. Misuse of this product can lead to an overdose that can lead to nausea, vomiting, diarrhea, hypotension, allergic reactions (itching and hives), dizziness, ataxia (balance problems), seizures, coma, and even death. Also, interactions with other medications, such as anticoagulants, should be taken into account.

Similarly, the FDA notes that it reviews drugs not only for the safety and efficacy of active ingredients, but also for inactive ingredients, and many of the inactive ingredients found in animal products are not evaluated for use in people or are included in a much larger quantity than those used in people. In some cases, it is not known how those inactive ingredients will affect the absorption of ivermectin in the human body.

If you have a prescription for ivermectin for FDA-approved use it must be obtained from a legitimate source, and the product taken exactly as prescribed.

Although he admits that some initial research is underway, the FDA has not reviewed the data supporting the use of ivermectin to treat or prevent COVID-19, and has not approved the drug for this use. So remember that taking a drug for unapproved use can be very dangerous, and this is also true for ivermectin.


https://t.co/TWb75xYEY4?amp=1

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

One Committed and Caring NC State Veterinary Student, So Many Choices

Like1
Dislike0

Dentalis Earns 5 VOHC® Seals, Positioning for Global Expansion in Animal Health

Like0
Dislike0

Advancing the 3Rs: innovation, implementation, ethics and society

Like0
Dislike0

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

Like0
Dislike0

Does Lung Function Imaging Modality Have a Dosimetric Impact On Functional Avoidance Treatment Planning: Assessment Using Prospective Clinical Trial Data

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top